MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the third ...

KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients — KRRO-110 did not reach projected levels of functional protein following a single adm ...

The notification has no immediate effect on the listing or trading of the Company’s Class A Ordinary Shares on Nasdaq. Nasdaq has provided the Company with a 180 calendar days compliance period, or ...

AI and 5G adoption drives demand as the Company sees positive cash flow with the highest operating margin in seven years TEL AVIV, Israel, Nov. 12, 2025 /PRNewswire/ ...